Obalon Therapeutics | SC 13D/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities (Amendment)

SEC · Jun 30, 2021 18:10

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Obalon Therapeutics | SC 13D/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities (Amendment)

Risk Disclaimer